Drug intelligence / Profile preview

Hyal-Joint

Development stage: Preclinical
Lead developer: Bioiberica
Administration: Oral

Overview

Hyal-Joint is a branded, natural extract derived from chicken combs, containing a high concentration (60%) of hyaluronic acid, along with collagen and other glycosaminoglycans. [10] It is marketed as an oral dietary supplement to support joint health, particularly for individuals with osteoarthritis. [4] Clinical evidence suggests that daily supplementation with Hyal-Joint can improve markers of quality of life, reduce joint pain, and enhance physical function in adults with knee osteoarthritis. [4, 18] Its proposed mechanism involves lubricating joints, maintaining the viscoelasticity of synovial fluid, and stimulating the body's own production of hyaluronic acid. [1, 2]

Brand names: Hyal-Joint
Other names: chicken comb extract

Targets

HMMRCD44 (CD44 antigen)

Beyond the preview

Go deeper on Hyal-Joint.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hyal-Joint.

Explore the full profile